KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Accured Expenses (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Change in Accured Expenses data on record, last reported at -$664.5 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 12205.56% year-over-year to -$664.5 million; the TTM value through Dec 2025 reached -$116.9 million, down 394.46%, while the annual FY2025 figure was -$116.9 million, 394.46% down from the prior year.
  • Change in Accured Expenses reached -$664.5 million in Q4 2025 per VRTX's latest filing, down from $588.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $588.8 million in Q3 2025 and bottomed at -$664.5 million in Q4 2025.
  • Average Change in Accured Expenses over 5 years is $60.0 million, with a median of $41.8 million recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 1534.34% in 2021, then tumbled 12205.56% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $372.7 million in 2021, then skyrocketed by 56.48% to $583.2 million in 2022, then tumbled by 52.67% to $276.0 million in 2023, then crashed by 101.96% to -$5.4 million in 2024, then crashed by 12205.56% to -$664.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$664.5 million in Q4 2025, $588.8 million in Q3 2025, and -$63.2 million in Q2 2025.